Clinical trials: Yellow Fever
Yellow Fever
Immunogenicity of Yellow Fever Vaccine in a Pediatric Population Vaccinated at 12-23 Months of Age in Argentina
Northern Argentina is a risk area for yellow fever (YF). Recent studies have suggested that immunity wanes in children vaccinated between 9 and 23 months of age.
- Trial name
- NCT05644145
- Testing
- Serological study after yellow fever vaccination
- Where
- 3 sites in Argentina
- Volunteers
- 361 people, healthy volunteers welcome
- Sponsor
- Ministry of Public Health, Argentina
Yellow Fever Vaccine, Yellow Fever
Yellow Fever Vaccine on Statin/ Non Statin Subjects
Since the 1st pandemic of the 21st century caused by SARS coronavirus, the world has experienced outbreaks of swine origin H1N1 influenza, Ebola and Zika viruses, which have all resulted in global health crises.
- Trial name
- NCT03116802
- Testing
- Stamaril (live attenuated yellow fever vaccine)
- Where
- Singapore
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Healthy
Yellow Fever Immune Response at Single Cell Resolution
The immune system is composed of diverse cell types with different functions that act together in order to defend against infection.
- Trial name
- NCT03458780
- Testing
- Yellow Fever Vaccine
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Yellow Fever Vaccine, Immunity
Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study)
The study main objective is to assess the immune status of children and adults who have never vaccinated, they will receive the first dose of 17DD yellow fever vaccine provided by the study and will be monitored for 10 years.
- Trial name
- NCT02555072
- Testing
- yellow fever vaccine
- Where
- 6 sites in Brazil
- Volunteers
- 4,761 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Yellow Fever, Encephalitis, Japanese
The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans
Epidemic viral diseases have become more prevalent in recent years. Among the various strategies to prevent such epidemics, vaccination is the most cost-effective.
- Trial name
- NCT01943305
- Testing
- Japanese Encephalitis vaccine, Yellow Fever vaccine
- Where
- Singapore
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Yellow Fever
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants
The study is designed as a Phase III, double-blind, multi-center, randomized, active-controlled study in which four groups of participants (n=554 per group) will receive either one of three different manufacturing lots of SII-YFV…
- Trial name
- NCT05447377
- Testing
- SII Yellow Fever Vaccine, STAMARIL®
- Where
- 2 sites in Mali, The Gambia
- Volunteers
- 2,216 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Yellow Fever Immunization
A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population
The purpose of this study is to determine whether vYF (investigational vaccine) is safe and can help the body to develop antibodies (immunogenicity) compared with Stamaril vaccine and YF-VAX vaccine (both licensed vaccines) and…
- Trial name
- NCT07103148
- Testing
- Yellow fever vaccine (live), Measles, combinations with mumps and rubella, live attenuated
- Where
- 15 sites in Honduras, Mexico and 1 more
- Volunteers
- 2,440 people, healthy volunteers welcome
- Sponsor
- Sanofi
Yellow Fever (Healthy Volunteers), Biopsy/Methods
Baseline Assessment of Skin Resident Memory T Cells in Healthy Unvaccinated Participants
In The main GeKoSkimm trial (= A randomized controlled trial to compare the immunogenicity and skin imprinting of intradermal, subcutaneous and intramuscular yellow fever vaccination) the investigators try to understand whether…
- Trial name
- NCT07636551
- Testing
- Skin punch biopsy, Blood samples
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria, Malaria Vaccines
Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of the SB257049 candidate malaria vaccine when co-administered with Vitamin A, measles, rubella and yellow fever vaccines to children aged 6…
- Trial name
- NCT02699099
- Testing
- Vitamin A, Candidate Plasmodium falciparum malaria vaccine, MR-Vac
- Where
- 2 sites in Ghana
- Volunteers
- 699 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dengue
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults
The main purpose of this study is to assess the immunogenicity and safety of the concomitant and sequential administration of yellow fever (YF) vaccine and tetravalent dengue vaccine (TDV) in healthy participants aged 18 to 60…
- Trial name
- NCT03342898
- Testing
- YF-17D, TDV
- Where
- 11 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Takeda
Malaria
Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen
This study is being done to assess the possibility of the potential integration of malaria vaccine into the EPI regimen. It will evaluate whether the malaria vaccine is safe and immunogenic in infants aged 6 to 10 weeks at first…
- Trial name
- NCT00436007
- Testing
- GSK 257049, Tritanrix™ HepB/Hib, Rouvax™
- Where
- 3 sites in Gabon, Ghana and 1 more
- Volunteers
- 511 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Treatment of Acute Yellow Fever Virus Infection
Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in Humans
Yellow Fever is an acute viral hemorrhagic disease caused by the Yellow Fever Virus (YFV), a re-emerging arbovirus transmitted by the same mosquito vector (Aedes aegypti) that transmits Dengue virus (DENV) and Zika virus (ZIKV).
- Trial name
- NCT03776786
- Testing
- TY014, 0.9% Saline
- Where
- Singapore
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Tysana Pte Ltd
Yellow Fever
Human Immune Responses to Yellow Fever Vaccination
The goal of this study is to use the live attenuated Yellow Fever Vaccine (YFV) as a safe and effective model for viral infection to understand human immune response to viral antigens.
- Trial name
- NCT00694655
- Testing
- Yellow Fever Vaccine, Leukapheresis, Fine-needle aspiration (FNA)
- Where
- United States
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Emory University
Immune System Responses and Trained Immunity After AS01 Administration, Healthy Adult
Improving Vaccine Protection for Adults
As people grow older, their immune system - the body's natural defence against diseases - becomes weaker, making them more vulnerable to infections and less responsive to vaccines.
- Trial name
- NCT07527247
- Testing
- AS01 adjuvant (0.5 mL intramuscular), YF17D (Stamaril, Sanofi-Pasteur)
- Where
- Singapore
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Yellow Fever Vaccine
VAC-SIP-YF (Vaccination- Safety & Immunogenicity During Pregnancy- Yellow Fever)
The aim of this study is to compare the immunogenicity induced by yellow fever vaccination administered during pregnancy with that induced by vaccination outside pregnancy, and to assess the maternal and fetal tolerance of this…
- Trial name
- VAC-SIP-YF (NCT06694766)
- Testing
- Blood sample collection
- Where
- France
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Yellow Fever
Trial of an Inactivated Yellow Fever Virus Vaccine
This trial will be a randomized, placebo controlled, double-blind (within dosing group), dose escalation Phase 1 trial, evaluating dosages of 1 mcg and 5 mcg of HydroVax-002 YFV vaccine given intramuscularly on Day 1 and Day 29…
- Trial name
- NCT05172544
- Testing
- HydroVax-002 YFV
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Najit Technologies, Inc.
Yellow Fever
Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children
In a previous study by the researchers' group, the researchers' investigate the duration of yellow fever post-vaccination immunity in vaccinated children between 9 and 23 months of age.
- Trial name
- NCT02990182
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
Yellow Fever
Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea
This is a passive enhance safety surveillance (ESS) of Stamaril® vaccine in Korea. The objective is to collect suspected related adverse events following vaccination with Stamaril® in routine practice.
- Trial name
- NCT03541694
- Testing
- Stamaril®
- Where
- South Korea
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Tuberculosis, Diphtheria
Evaluation of an Infant Immunization Encouragement Program in Nigeria
Previous studies have shown that a small incentive can have a large impact on health behaviors like vaccinating children. New Incentives, an international non-governmental organization (NGO), aims to boost demand for immunization…
- Conditions
- Tuberculosis, Diphtheria, Tetanus, Pertussis
- Trial name
- NCT03870061
- Testing
- All Babies Are Equal Initiative (conditional cash transfer program)
- Where
- 3 sites in Nigeria
- Volunteers
- 5,187 people, healthy volunteers welcome
- Sponsor
- GiveWell